Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 17/20 | 0.40 |
| ▸ | CA2 | P00918 | 17/20 | 0.40 |
| ▸ | CA9 | Q16790 | 17/20 | 0.40 |
| ▸ | CA1 | P00915 | 16/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 11/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249227 | 0.89 | PDE10A (0.37) | CA12CA2CA9CA1LMNA | |
| SCHEMBL10249278 | 0.88 | PDE10A (0.36) | CA12CA2CA9CA1PDE10A | |
| SCHEMBL10249250 | 0.87 | PDE10A (0.38) | CA12CA2CA9CA1CA14 | |
| SCHEMBL10249035 | 0.86 | BRD4 (0.36) | PDE10AAKT1AKT2 | |
| SCHEMBL10284733 | 0.85 | PTGS2 (0.42) | CA12CA2CA9CA1CA14 | |
| SCHEMBL10249307 | 0.81 | PDE10A (0.38) | LMNAPDE10AAKT1AKT2 | |
| SCHEMBL4403186 | 0.81 | PDE10A (0.40) | PDE10AAKT1AKT2 | |
| SCHEMBL16803686 | 0.80 | PDE10A (0.38) | LMNAPDE10AAKT1AKT2 | |
| SCHEMBL10249224 | 0.79 | PDE10A (0.40) | LMNAPDE10AAKT1AKT2 | |
| SCHEMBL10248903 | 0.79 | POLB (0.38) | PDE10AAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | CA12 3308/4885CA2 3296/4885CA9 3380/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | CA12 3308/4885CA2 3296/4885CA9 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.